Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Osr Health Inc (OSRH)

Osr Health Inc (OSRH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
CORRECTION FROM SOURCE: Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target ACCESS Newswire - Thu Jul 2, 12:05PM CDT

The tiered reward structure only has to be at or above the specified price level on the 3, 6, 9, or 12 month observation date. It was previously mentioned that the pricing needed to be sustained over that...

OSRH : 0.4856 (+15.51%)
Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target ACCESS Newswire - Thu Jul 2, 8:00AM CDT

NEW YORK CITY, NY / ACCESS Newswire / July 2, 2026 / Emerging Growth Research today issued a flash report on OSR Health, Inc. (NASDAQ:OSRH), formerly OSR Holdings, reaffirming its Buy-Emerging rating and...

OSRH : 0.4856 (+15.51%)
OSR Health Announces Shareholder Loyalty Program to Reward Conviction Holders With Additional Shares ACCESS Newswire - Thu Jun 25, 7:32AM CDT

Contingent Value Rights would reward continuous holders with additional shares as the Company meets defined price milestones

OSRH : 0.4856 (+15.51%)
Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target ACCESS Newswire - Tue May 5, 8:05AM CDT

NEW YORK, NY / ACCESS Newswire / May 5, 2026 / Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price target of...

OSRH : 0.4856 (+15.51%)
Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target ACCESS Newswire - Fri Mar 27, 4:00AM CDT

NEW YORK CITY, NY / ACCESS Newswire / March 27, 2026 / Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price target...

OSRH : 0.4856 (+15.51%)
Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials PR Newswire - Thu Mar 19, 8:44AM CDT

BELLEVUE, Wash. , March 19, 2026 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a healthcare-focused holding company advancing innovative medical technologies, today announced that its subsidiary,...

OSRH : 0.4856 (+15.51%)
Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch PR Newswire - Thu Jan 22, 8:55AM CST

BELLEVUE, Wash. , Jan. 22, 2026 /PRNewswire/ -- Woori IO, an OSR company developing next-generation noninvasive glucose monitoring technologies, today commented on the U.S. Food and Drug Administration's...

OSRH : 0.4856 (+15.51%)
Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform PR Newswire - Fri Jan 16, 8:20AM CST

BELLEVUE, Wash. , Jan. 16, 2026 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneer in oral T-cell immunotherapies for cancer, today announced the appointment of Sébastien...

OSRH : 0.4856 (+15.51%)
Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones PR Newswire - Mon Jan 12, 7:05AM CST

BELLVUE, Wash. , Jan. 12, 2026 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) today announced that its Swiss biotechnology subsidiary, Vaximm AG, has received a binding term sheet from BCM Europe...

OSRH : 0.4856 (+15.51%)
Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings PR Newswire - Fri Dec 19, 2025

Company advancing dual clinical pathways, including a Samsung-supported PoC trial in Korea and a planned U.S. FDA trial with a leading California research university

OSRH : 0.4856 (+15.51%)

Barchart Exclusives

This Dividend King With a 64-Year Streak Is Beating the Market Barchart - Thu Jul 16, 6:30PM CDT
This Dividend King continues to beat the market by pairing reliable income with consistent business growth. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.